title: Infusions of allogeneic natural killer cells as cancer therapy.
abstract: Natural killer (NK) cells are normal white blood cells capable of killing malignant cells without prior sensitization. Allogeneic NK cell infusions are attractive for cancer therapy because of non-cross-resistant mechanisms of action and minimal overlapping toxicities with standard cancer treatments. Although NK therapy is promising, many obstacles will need to be overcome, including insufficient cell numbers, failure of homing to tumor sites, effector dysfunction, exhaustion, and tumor cell evasion. Capitalizing on the wealth of knowledge generated by recent NK cell biology studies and the advancements in biotechnology, substantial progress has been made recently in improving therapeutic efficiency and reducing side effects. A multipronged strategy is essential, including immunogenetic-based donor selection, refined NK cell bioprocessing, and novel augmentation techniques, to improve NK function and to reduce tumor resistance. Although data from clinical trials are currently limited primarily to hematologic malignancies, broader applications to a wide spectrum of adult and pediatric cancers are under way. The unique properties of human NK cells open up a new arena of novel cell-based immunotherapy against cancers that are resistant to contemporary therapies.
authors.affiliation: Author's Affiliations: Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital; and Department of Pediatrics, University of Tennessee, Memphis, Tennessee wing.leung@stjude.org.
authors.forename: Wing
authors.initials: W
authors.lastname: Leung
mesh_terms: D000818:Animals; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000592:standards; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011785:Quality Assurance, Health Care; D054340:Receptors, KIR / Q000235:genetics / Q000378:metabolism; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D054340:Receptors, KIR